Leukeran (Chlorambucil)

Chlorambucil belongs to the nitrogen‑mustard class of alkylating agents. It binds covalently to DNA, forming cross‑links that prevent DNA replication and transcription. This damage triggers programmed cell death, particularly in rapidly dividing malignant lymphocytes.

The dosage of Leukeran is individualized and determined by the prescribing physician based on the patient’s diagnosis, disease stage, body surface area, and laboratory parameters. Only a qualified healthcare professional should set the dosing schedule.

Safety data for chlorambucil during pregnancy and lactation are limited. The drug is generally avoided in pregnant or nursing women because of potential fetal toxicity and secretion in breast milk. Women of child‑bearing potential should use effective contraception and discuss risks with their physician.

To order Leukeran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Leukeran (chlorambucil) is an oral alkylating agent, whereas alternatives such as cyclophosphamide are also alkylators but often administered intravenously. Chlorambucil offers the convenience of oral dosing and a slightly different toxicity profile, with less acute nausea but comparable myelosuppression.

Leukeran tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep out of reach of children and do not use if the packaging is damaged.

Leukeran is taken orally as a tablet, usually with a glass of water. It may be taken with or without food, but patients should follow the specific instructions provided by their healthcare provider to maintain consistent absorption.

The most serious risks include severe myelosuppression leading to anemia, neutropenia or thrombocytopenia, which can cause infection, bleeding or fatigue. Secondary malignancies and pulmonary toxicity are rare but serious complications that require prompt medical attention.

Leukeran should not be used in patients with known hypersensitivity to chlorambucil or other nitrogen‑mustard agents, those with severe bone‑marrow suppression, active uncontrolled infections, or pregnant women unless the potential benefit justifies the risk. Clinicians must evaluate each case individually.